- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Deloitte Radical Interoperability Survey Results
Deloitte-audit, consulting, tax, and advisory services company-announced the results of its Radical Interoperability survey, conducted by the Deloitte Center for Health Solutions.
The report provides insights for healthcare stakeholders that want to emerge as a leader in their use of data and analytics in the future of health. This includes the need to prioritize interoperability at the leadership level; developing a bold investment strategy that focuses on strategic, future-looking opportunities; and leveraging the coming compliance, privacy, and security regulations as a key catalyst to drive enterprise momentum.
The report identifies that while regulations are one of the biggest drivers (47%) for broader interoperability, value-based care is the greatest driver (51%) in this pursuit. Furthermore, a recognition of consumer demand for transparency and access-particularly among younger generations-is one of the top drivers (41%).
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
